These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
175 related items for PubMed ID: 9622543
1. Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency. Han Q, Chang CH, Li R, Ru Y, Jadhav PK, Lam PY. J Med Chem; 1998 Jun 04; 41(12):2019-28. PubMed ID: 9622543 [Abstract] [Full Text] [Related]
7. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors. Smith AB, Cantin LD, Pasternak A, Guise-Zawacki L, Yao W, Charnley AK, Barbosa J, Sprengeler PA, Hirschmann R, Munshi S, Olsen DB, Schleif WA, Kuo LC. J Med Chem; 2003 May 08; 46(10):1831-44. PubMed ID: 12723947 [Abstract] [Full Text] [Related]
8. Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors. De Lucca GV, Liang J, De Lucca I. J Med Chem; 1999 Jan 14; 42(1):135-52. PubMed ID: 9888839 [Abstract] [Full Text] [Related]
9. Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis. Nugiel DA, Jacobs K, Cornelius L, Chang CH, Jadhav PK, Holler ER, Klabe RM, Bacheler LT, Cordova B, Garber S, Reid C, Logue KA, Gorey-Feret LJ, Lam GN, Erickson-Viitanen S, Seitz SP. J Med Chem; 1997 May 09; 40(10):1465-74. PubMed ID: 9154969 [Abstract] [Full Text] [Related]
10. Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds. Spaltenstein A, Almond MR, Bock WJ, Cleary DG, Furfine ES, Hazen RJ, Kazmierski WM, Salituro FG, Tung RD, Wright LL. Bioorg Med Chem Lett; 2000 Jun 05; 10(11):1159-62. PubMed ID: 10866371 [Abstract] [Full Text] [Related]
11. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. Kaldor SW, Kalish VJ, Davies JF, Shetty BV, Fritz JE, Appelt K, Burgess JA, Campanale KM, Chirgadze NY, Clawson DK, Dressman BA, Hatch SD, Khalil DA, Kosa MB, Lubbehusen PP, Muesing MA, Patick AK, Reich SH, Su KS, Tatlock JH. J Med Chem; 1997 Nov 21; 40(24):3979-85. PubMed ID: 9397180 [Abstract] [Full Text] [Related]
17. A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease. Sham HL, Zhao C, Stewart KD, Betebenner DA, Lin S, Park CH, Kong XP, Rosenbrook W, Herrin T, Madigan D, Vasavanonda S, Lyons N, Molla A, Saldivar A, Marsh KC, McDonald E, Wideburg NE, Denissen JF, Robins T, Kempf DJ, Plattner JJ, Norbeck DW. J Med Chem; 1996 Jan 19; 39(2):392-7. PubMed ID: 8558507 [Abstract] [Full Text] [Related]
19. Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors. Randolph JT, Huang PP, Flosi WJ, DeGoey D, Klein LL, Yeung CM, Flentge C, Sun M, Zhao C, Dekhtyar T, Mo H, Colletti L, Kati W, Marsh KC, Molla A, Kempf DJ. Bioorg Med Chem; 2006 Jun 15; 14(12):4035-46. PubMed ID: 16504523 [Abstract] [Full Text] [Related]